SOLASCURE Ltd (SolasCure), a biotechnology firm creating a novel therapy to rework continual wound care, immediately introduced it has been chosen for Innovate UK’s World Incubator Programme in Houston, US. The programme, which is concentrated on commercialising progressive options for unmet healthcare wants, is delivered in partnership with the Texas Medical Centre (TMC), the biggest medical advanced globally. The programme will assist the long run entry of Aurase Wound Gel, SolasCure’s first investigational product for the therapy of hundreds of thousands of sufferers with continual wounds worldwide, into the US market.
SolasCure is one in every of 16 healthcare corporations chosen for the World Incubator Programme in Houston. The Firm’s participation within the programme builds on the latest European Innovation Council’s Accelerator Grant and Innovate UK Biomedical Catalyst Grant wins to additional advance the event of Aurase Wound Gel.
The 6-month World Incubator Programme is totally funded by Innovate UK and consists of two intensive market visits to Houston, a dynamic well being analysis hub with over 1,760 life science corporations, healthcare services and analysis establishments. These visits will deal with buyer discovery, mentorship, and investor networking, together with engagement with hospital directors, procurement, and reimbursement professionals, to assist the long run entry of Aurase Wound Gel for the US market.
It’s a actual increase to our journey at SolasCure to be chosen for this World Incubator Programme, persevering with the momentum from our latest EIC Accelerator and the BMC grant wins. This represents one other key piece of trade validation and recognition by TMC/TMC-Innovation, international leaders in medical innovation, that SolasCure has the potential to deal with an enormous unmet want,”
Lee Harle, Chief Govt Officer, SolasCure
“TMC is the biggest medical advanced on the planet and getting access to this experience and community might be invaluable in strengthening our plans for SolasCure and Aurase Wound Gel within the US.”
